Therapeutics Alliances News & Events
Partnerships formed by Therapeutics Alliances, NYU researchers, and biopharma companies, investors, and nonprofits have resulted in novel therapies that have the potential to transform healthcare. Read our latest news coverage to learn more.
Nadim Shohdy, PhD, director and assistant dean of Therapeutics Alliances, talks with WuXi AppTec about merging academic science with industry to accelerate drug discovery.
FutuRx launches GliXogen Therapeutics to develop novel therapies for multiple sclerosis and other demyelinating disorders.
MRC Technology collaborates with NYU School of Medicine to develop biologics for inflammatory bone disease.
Abzena signs protein engineering agreement with NYU Langone Health.
Axxam executes agreement with NYU Langone Medical Center for the provision of drug discovery services.
Allied-Bristol Life Sciences launches iβeCa Therapeutics from NYU School of Medicine to develop novel cancer therapeutics targeting the Wnt pathway.
PureTech Health advances new program targeting immunosuppressive gamma delta T cells and related mechanisms.
Repare Therapeutics raises $68 million Series A.
Heptares Therapeutics enters a new research and drug discovery collaboration under its 'Orbit' initiative with NYU School of Medicine.